person · Reporting owner
Heffernan Michael Thomas
Disclosed activity across 9 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 02, 2021 | June 03, 2021 |
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | June 02, 2026 | June 04, 2026 |
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 03, 2022 |
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | February 10, 2025 | February 12, 2025 |
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | June 22, 2023 | June 26, 2023 |
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Director | September 15, 2026 | September 17, 2026 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Director | June 16, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 02, 2021 · Filed June 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,586 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 13,700 · Balance 48,586 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2031-06-02 | Direct | 20,100 |
Reported balance
After 2021-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-02 · Grant · Acquired 20,100 · Balance 20,100 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
Avalo Therapeutics, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.96 · Expires 2036-06-02 | Direct | 29,500 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 29,500 · Balance 29,500 F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 3,320 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.30 · Expires 2030-01-31 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 26,200 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 10, 2025 · Filed February 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,328 |
Reported balance
After 2025-02-10 transaction · row 1
1 source rowRow 1 · 2025-02-10 · Grant · Acquired 4,820 · Balance 50,328 F1: Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
SYNLOGIC, INC.
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-22 | Direct | 30,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.
Trevi Therapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,351 |
Ending reported balance
After 2026-09-15 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 18,421 · Balance 24,772 Row 2 · 2026-09-15 · Sale · Disposed 18,321 · Balance 6,451 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 3 · 2026-09-15 · Sale · Disposed 100 · Balance 6,351 F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 4 · 2026-09-15 · Exercise / conversion · Acquired 21,052 · Balance 27,403 Row 5 · 2026-09-15 · Sale · Disposed 20,952 · Balance 6,451 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 6 · 2026-09-15 · Sale · Disposed 100 · Balance 6,351 F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 18,421 · Balance 0 F3: These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. F4: These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 21,052 · Balance 0 F5: These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. F6: These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3: These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.
F4: These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027.
F5: These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.
F6: These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027.
enGene Therapeutics Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2036-06-16 | Direct | 31,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,000 · Balance 31,000 F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KERYX BIOPHARMACEUTICALS INC
Report date December 12, 2018 · Filed December 13, 2018
Section 16 reporting ended · disclosed 2018-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 1
1 source rowRow 1 · 2018-12-12 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 16,666 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. |
| Stock OptionSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-12 · Disposition to issuer · Disposed 110,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement.
F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 16,666 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.
F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2020 Filed May 15, 2020 20:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 11,969 | $21.21 | $253,862.49 |
DisclosureSEC source: 0001192482-20-000348 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,701 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2019. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.01 to $22.00, inclusive. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,380 | $20.92 | $28,869.60 |
DisclosureSEC source: 0001192482-20-000348 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,670 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2019. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.87 to $20.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:14 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $47.10 | $0.00 |
DisclosureSEC source: 0001562180-20-003254 · primarydocument.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2030-04-29 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2021 or (b) the date of the 2021 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 30, 2020 Filed Mar 26, 2021 16:14 UTC Amendment | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 0 | $0.00 Strike: $47.10 | $0.00 |
DisclosureSEC source: 0001562180-21-002443 · primarydocument.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 0 shares Expires 2030-04-29 F3 · shares: On May 1, 2020, the reporting person filed a Form 4 in respect of 18,000 options granted pursuant to the issuer's non-employee director compensation policy. The issuer subsequently determined that all 18,000 of the options comprising such award were null and void upon grant as a result of the $1,000,000 annual limit for non-employee director compensation under its 2017 Equity Incentive Plan. F4 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2021 or (b) the date of the 2021 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,962 | $21.62 | $107,278.44 |
DisclosureSEC source: 0001192482-20-000148 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,050 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 31, 2020 Filed Jan 31, 2020 19:37 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $48.49 | $0.00 |
DisclosureSEC source: 0001562180-20-000723 · primarydocument.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Shares · 36,000 shares Expires 2030-01-31 F1 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on January 31, 2021, 2022 and 2023, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
| January 31, 2020 Filed Mar 26, 2021 16:14 UTC Amendment | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (right to buy) · Derivative | 26,200 | $0.00 Strike: $48.49 | $0.00 |
DisclosureSEC source: 0001562180-21-002443 · primarydocument.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,200 Underlying: Common Shares · 26,200 shares Expires 2030-01-31 F1 · shares: On January 31, 2020, the reporting person filed a Form 4 in respect of 36,000 options granted pursuant to the issuer's non-employee director compensation policy. The issuer subsequently determined that 9,800 of the options comprising such award were null and void upon grant as a result of the $1,000,000 annual limit for non-employee director compensation under its 2017 Equity Incentive Plan. F2 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on January 31, 2021, 2022 and 2023, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 21:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 275,463 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001192482-20-000046 · edgar.xml · derivative · entry 5 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,463 shares Expires 2025-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All of the 275,463 option shares are exercisable. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 21:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 787 | $21.56 | $16,967.72 |
DisclosureSEC source: 0001192482-20-000046 · edgar.xml · nonDerivative · entry 4 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,012 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 21:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 32,700 | $22.69 | $741,963.00 |
DisclosureSEC source: 0001192482-20-000046 · edgar.xml · nonDerivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,799 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2019. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.42 to $23.30, inclusive. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 21:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 262,587 | $21.84 | $5,734,900.08 |
DisclosureSEC source: 0001192482-20-000046 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,499 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2019. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.42 to $22.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 21:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 275,463 | $5.73 | $1,578,402.99 |
DisclosureSEC source: 0001192482-20-000046 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 20:45 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,779 | $11.24 | $53,715.96 |
DisclosureSEC source: 0001192482-19-000337 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,623 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 19, 2019 Filed Jul 23, 2019 20:03 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 667 | $10.35 | $6,903.45 |
DisclosureSEC source: 0001192482-19-000320 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,402 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 25,000 | $11.26 | $281,500.00 |
DisclosureSEC source: 0001192482-19-000315 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.11 to $11.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2). Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 22:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 2,021 | $12.05 | $24,353.05 |
DisclosureSEC source: 0001192482-19-000295 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.10, inclusive. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 22:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 22,979 | $11.31 | $259,892.49 |
DisclosureSEC source: 0001192482-19-000295 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,090 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.06 to $11.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001562180-19-003437 · primarydocument.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2029-06-06 F2 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003437 · primarydocument.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,186 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:04 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 6,517 | $13.13 | $85,568.21 |
DisclosureSEC source: 0001192482-19-000260 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.43, inclusive. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:04 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 18,483 | $12.74 | $235,473.42 |
DisclosureSEC source: 0001192482-19-000260 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,586 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.41 to $12.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | ConversionSeries C Preferred Stock · Derivative | 34,247 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013257 · doc4.xml · derivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,851 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | PurchaseCommon Stock | 2,500 | $10.00 | $25,000.00 |
DisclosureSEC source: 0000899243-19-013257 · doc4.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,351 Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | ConversionCommon Stock | 3,851 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-013257 · doc4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| May 07, 2019 Filed May 8, 2019 21:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 23,684 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000899243-19-012653 · doc4.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,684 Underlying: Common Stock · 23,684 shares Expires 2029-05-06 F1 · derivative.exercise_date: This option was granted on May 7, 2019, effective upon the pricing of the Issuer's initial public offering. This option is scheduled to vest as to (i) 50% of the underlying shares on the earlier of (A) the first anniversary of the date of grant and (B) the date of the first annual meeting of stockholders of the Issuer held following the date of grant and (ii) the remaining 50% of the underlying shares on the earlier of (A) the second anniversary of the date of grant and (B) the date of the second annual meeting of stockholders of the Issuer held following the date of grant. Read SEC document |
| April 25, 2019 Filed Apr 30, 2019 12:52 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 9,414 | $0.00 Strike: $14.57 | $0.00 |
DisclosureSEC source: 0001192482-19-000235 · edgar.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,414 Underlying: Common Stock · 9,414 shares Expires 2029-04-25 F2 · derivative.exercise_date: The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer. Read SEC document |
| April 25, 2019 Filed Apr 30, 2019 12:52 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000235 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,069 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:24 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,808 | $15.87 | $76,302.96 |
DisclosureSEC source: 0001192482-19-000199 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,362 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.64 to $16.22, inclusive. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:24 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 20,192 | $14.91 | $301,062.72 |
DisclosureSEC source: 0001192482-19-000199 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,170 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.64 to $15.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 21:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 25,000 | $17.17 | $429,250.00 |
DisclosureSEC source: 0001192482-19-000165 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,362 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.89 to $17.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 7,068 | $15.06 | $106,444.08 |
DisclosureSEC source: 0001192482-19-000102 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,362 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.14, inclusive. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 17,932 | $14.71 | $263,779.72 |
DisclosureSEC source: 0001192482-19-000102 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,430 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.03 to $14.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 7,851 | $14.39 | $112,975.89 |
DisclosureSEC source: 0001192482-19-000077 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,362 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 787 | $15.76 | $12,403.12 |
DisclosureSEC source: 0001192482-19-000039 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,213 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 25,000 | $15.56 | $389,000.00 |
DisclosureSEC source: 0001192482-19-000030 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.31 to $16.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2). Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 22:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 3,313 | $18.57 | $61,522.41 |
DisclosureSEC source: 0001192482-18-000506 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2018. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.50 to $18.65, inclusive. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 22:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 21,687 | $18.12 | $392,968.44 |
DisclosureSEC source: 0001192482-18-000506 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,313 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.50 to $18.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:35 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | Disposition to issuerStock Option · Derivative | 110,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030886 · doc4.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · price: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:35 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | Disposition to issuerCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030886 · doc4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2 · shares: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 16,666 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2 · price: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 16,666 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:38 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0000899243-18-030945 · doc4.xml · derivative · entry 5 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-12-12 F4 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:38 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 11,229 | Not disclosed Strike: $10.05 | Not disclosed |
DisclosureSEC source: 0000899243-18-030945 · doc4.xml · derivative · entry 4 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2028-06-30 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:38 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 11,229 | Not disclosed Strike: $17.53 | Not disclosed |
DisclosureSEC source: 0000899243-18-030945 · doc4.xml · derivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2027-06-09 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:38 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 18,716 | Not disclosed Strike: $16.17 | Not disclosed |
DisclosureSEC source: 0000899243-18-030945 · doc4.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,716 Underlying: Common Stock · 18,716 shares Expires 2026-06-21 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:38 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 7,486 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030945 · doc4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,486 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. ("Keryx") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time") was automatically converted into 0.37433 shares of the Issuer's common stock (the "Exchange Multiplier"). Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:19 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 3,600 | $17.05 | $61,380.00 |
DisclosureSEC source: 0001192482-18-000479 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2018. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.06, inclusive. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:19 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 21,400 | $16.53 | $353,742.00 |
DisclosureSEC source: 0001192482-18-000479 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:27 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 25,000 | $16.53 | $413,250.00 |
DisclosureSEC source: 0001192482-18-000460 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.40 to $16.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2). Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 20:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,025 | $18.03 | $36,510.75 |
DisclosureSEC source: 0001192482-18-000414 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,000 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 21:41 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 668 | $20.15 | $13,460.20 |
DisclosureSEC source: 0001192482-18-000378 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,025 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| June 30, 2018 Filed Jul 12, 2018 17:59 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantStock Options (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001114220-18-000074 · wf-form4_153143273940791.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-30 F3 · derivative.exercise_date: The 30,000 stock options vest as to one-third on each of June 30, 2019, June 30, 2020 and June 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.